BTIG Reiterates Buy on Ascentage Pharma Group, Maintains $48 Price Target
BTIG analyst Jeet Mukherjee reiterates Ascentage Pharma Group (NASDAQ:AAPG) with a Buy and maintains $48 price target.
Read original at benzingaStocks · News reference
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers VolitionRX (AMEX:VNRX) shares increased by 102.2% to $0.69 during Thursday's pre-market session. The company's market cap stands at $4.8 million. NewcelX (NASDAQ:NCEL) shares increased by 15.08% to
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 27, 2026, 12:05 PM
- Checked
- Aug 27, 2026, 12:05 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Transcript: Ascentage Pharma Group H1 2026 Earnings Conference Call
On Thursday, Ascentage Pharma Group (NASDAQ:AAPG) discussed quarterly financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Read original at benzingaReported Earlier, Ascentage Pharma Group H1 EPS $(0.32) Beats $(0.44) Estimate, Sales $44.541M Beat $24.070M Estimate
Read original at benzingaAscentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
Ascentage Pharma announced the appointment of Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer to strengthen global business development and US commercialization efforts. Both executives bring extensive experience in oncology and specialty therapeutics, with the company advancing multiple Phase III registrational studies for its pipeline of cancer therapies.
Read original at globenewswire-incAC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline
AC Immune reports favorable interim Phase 1 results for ACI-19764, an oral NLRP3 inhibitor showing strong safety and brain penetration.
Read original at benzingaBTIG Reiterates Buy on AC Immune, Maintains $8 Price Target
BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.
Read original at benzinga